Pilot clinical study to evaluate the anticoagulant activity of fucoidan
Pilot clinical study to evaluate the anticoagulant activity of fucoidan
复制标题
DOI：
10.1097/mbc.0b013e32833135fe
复制
发表时间：
2009-10-01
影响因子：
1.1
通讯作者：
Lowenthal, Ray M.
中科院分区：
文献类型：
--
作者：
Irhimeh, Mohammad R.;Fitton, J. Helen;Lowenthal, Ray M.
海藻衍生的肝素类物质，如岩藻糖胶，在体外作为潜在的抗凝血剂已被广泛研究。然而，目前还没有关于口服岩藻糖胶的抗凝血活性的人体研究。本临床试验旨在评价岩藻多糖胶摄取止血的安全性和临床疗效，并研究其体外抗凝活性。在单盲临床试验中，共20名志愿者被分配到安慰剂组(n=10)和积极治疗组(n=10)，安慰剂组(n=10)服用3g瓜尔豆胶胶囊，积极治疗组(n=10)服用3g 75%岩藻糖胶胶囊，为期12天。按标准方法分析血小板指数、活化部分凝血活酶时间、抗凝血酶-Ⅲ、凝血酶时间、凝血酶原时间、抗凝血因子-Xa。在体内，活化部分凝血活酶时间从28.41增加到34.01 S(n=10，P=0.01)，凝血酶时间从18.62减少到17.55 S(n=10，P=0.04)，抗凝血酶-Ⅲ从113.5增加到117%(n=10，P=0.03)。褐藻糖胶的体外抗凝血活性显著。使活化部分凝血活酶时间、凝血酶时间、凝血酶原时间延长，而抗凝血酶-III降低。岩藻糖胶的体内止血作用不明显，可能与肠道吸收低有关。因此，本研究中使用的形式的岩藻糖胶似乎没有口服抗凝血活性，但它在体外具有非常强的抗凝血活性。血凝纤维蛋白溶解20：607-610(C)2009沃尔特斯·克鲁沃健康垂直条Lippincott Williams&Wilkins。
Seaweed-derived heparin-like substances such as fucoidan have been extensively studied in vitro as potential blood anticoagulants. However, there have been no human studies investigating the anticoagulant activity of fucoidan when administered orally. This pilot clinical trial was aimed to assess the safety and clinical effects of fucoidan ingestion on hemostasis as well as study its in-vitro anticoagulant activity. In a single-blinded clinical trial, a total of 20 human volunteers were allocated to both the placebo group (n = 10) who ingested 3 g of guar gum capsules and to the active treatment group (n = 10) who ingested 3 g of 75% fucoidan capsules for 12 days. Platelet indices, activated partial thromboplastin time, antithrombin-III, thrombin time, prothrombin time, and antifactor-Xa were analyzed according to standard methods. In vivo, activated partial thromboplastin time increased from 28.41 to 34.01 s (n = 10, P = 0.01), thrombin time decreased from 18.62 to 17.55 s (n = 10, P = 0.04), and antithrombin-III increased from 113.5 to 117% (n = 10, P = 0.03). The in-vitro fucoidan anticoagulant activity was found prominent. It increased activated partial thromboplastin time, thrombin time, and prothrombin time, whereas antithrombin-III decreased. In-vivo effect of fucoidan on hemostasis was not obvious probably due to low intestinal absorption. Thus, fucoidan in the form used in this study does not seem to have an oral anticoagulant activity, but it has a very strong in-vitro anticoagulant activity. Blood Coagul Fibrinolysis 20:607-610 (C) 2009 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.